Veeva Systems (VEEV)
Health Care · Life Sciences Cloud Software · NYSE
Veeva is the dominant cloud software and data platform powering the global life sciences industry from drug development through commercialization, with AI-enhanced solutions and a 16% annual revenue growth trajectory.
What Veeva Systems does
Veeva is the leading provider of industry cloud solutions for the global life sciences industry, serving pharmaceutical, biotechnology, medical device, and diagnostics companies. The company offers four major product categories—Development Cloud, Quality Cloud, Commercial Cloud, and Data Cloud—spanning cloud software, AI, data, and business consulting to support customers from R&D through commercialization. Veeva's solutions help life sciences companies develop and bring products to market faster, market and sell more effectively, and maintain regulatory compliance.
Themes: life sciences cloud solutions, clinical trial software, drug development, regulatory compliance, clinical data management, pharmaceutical commercialization, AI in pharma, quality and manufacturing, patient engagement
Fundamentals
- Price$248.46 as of 2026-08-24 close
- Market cap$40.4B as of 2026-08-24
- 1-year return-14.6% 2025-08-22 close $290.86 → 2026-08-24 close $248.46
- P/E43.95 as of 2026-08-24
- Net margin+28.4% as of 2026-08-24
- Gross margin+75.0% as of 2026-08-24
- ROE+13.4% as of 2026-08-24
- Debt / equity0.00 as of 2026-08-24
- Revenue growth (YoY)+16.3% as of 2026-08-24
- Revenue CAGR (3y)+14.0% SEC XBRL
- Beta0.65 as of 2026-08-24
- Last reported earnings2026-06-03 SEC EDGAR Form 8-K (Item 2.02)
How VEEV compares in its sector
- price-to-earnings ratiomiddle range 191 covered Health Care peers, as of 2026-08-24
- net profit margintop 10% 504 covered Health Care peers, as of 2026-08-24
- operating margintop 10% 504 covered Health Care peers, as of 2026-08-24
- gross marginmiddle range 384 covered Health Care peers, as of 2026-08-24
- return on equitytop 25% 576 covered Health Care peers, as of 2026-08-24
- 3-year revenue CAGRmiddle range 402 covered Health Care peers
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
Top 10 scores & list membership
VEEV is in the Health Care Short-term Top 10.
Health Care Short-term Top 10 — since 18 Aug 2026
Long-term score
58.1 #354 of 1,605 scored · #38 of 195 in Health Care
Financial health 96th (free cash flow margin 49.4%, debt to equity 0) and growth 72nd (3-year revenue CAGR 14%, revenue growth year over year 16.3%); weakest is capital return (18th, consecutive years of dividend increases 0 years).
Short-term score
62.7 #103 of 1,698 scored · #28 of 236 in Health Care
Trend 80th: the price is 29% above the average price paid over the period covered, so the typical buyer over that stretch is showing a gain; momentum 69th: over the past 3 months this stock beat the market by 52.7 percentage points; weakest is catalysts 45th: the analyst consensus rating has softened toward "sell" since the prior reading.
In this list since 18 Aug 2026 — currently 7th in the list (3 days)
- Entered 18 Aug 2026: first selection for this list at rank 5, score 67.6.
Scores as of 24 Aug 2026. Each bar is a percentile: how this company ranked against every company the score ranked, 0–100. A list is a published formula and its output, not a recommendation. Method version 3.
How Veeva Systems looks technically
Veeva Systems (VEEV) is trading 23.7% above its 200-day average, the long-term trend line — a longer-term uptrend. Its 50-day average crossed below its 200-day average about 165 trading days ago — a "death cross", a bearish long-term signal. A strong uptrend is in place — ADX, a 0–100 trend-strength gauge, is 45, with buyers in control. Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 70, neither overbought (above 70) nor oversold (below 30). It made a new 20-day high about 8 trading days ago. It is 20.0% below its highest point of the past year.
Trend
9
| Distance from the 200-day | it is trading 23.7% above its 200-day average, the long-term trend line — a longer-term uptrend | +23.7% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $199.40 | $199.40 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $200.79 | $200.79 |
| Swing structure | each recent peak has been higher than the one before it and each dip has been shallower — the pattern chart-watchers call an uptrend, which describes where price has already been and not where it goes next | higher highs and higher lows |
| Last swing turn | its last significant turn was a swing low 32 calendar days ago — the swings before that are what the structure reading is measured on | 32 sessions |
| Wave structure | its recent swings can be read as a five-part upward sequence — what Elliott-wave chartists call an impulse — now in leg 3 of five; the labelling fails if price closes below 179.25. It is one of several labellings that fit, and it describes the swings already printed, not what comes next. The same swings also read as a three-part correction in leg C. | possible upward five-wave sequence, in wave 3 (one of several readings) |
| Since the 50/200 cross | its 50-day average crossed below its 200-day average about 165 trading days ago — a "death cross", a bearish long-term signal | 165 sessions |
| Above the 200-day after a dip | it recently dipped to its 200-day average (the long-term trend line) and has since climbed back above it — now about 23.7% above | +23.7% |
| Trend strength (14-day ADX) | a strong uptrend is in place — ADX, a 0–100 trend-strength gauge, is 45, with buyers in control | 45.1 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 70, neither overbought (above 70) nor oversold (below 30) | 69.9 |
|---|---|---|
| Position in its 14-day range | it is trading near the top of its 14-day range ($208.07 to $253.49) — its "stochastic" reading is 89 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been slipping within that range over the last few sessions. | 88.9 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, is in positive territory (momentum leaning bullish) | 19 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $310.50 | $310.50 |
|---|---|---|
| From the 52-week high | it is 20.0% below its 52-week high (its highest price of the past year) | -20.0% |
| Above the 52-week low | it is 67.8% above its 52-week low (its lowest price of the past year) | +67.8% |
| Below the 52-week high | it is 20.0% below its highest point of the past year | 20.0% |
| Since a 20-day breakout | it made a new 20-day high about 8 trading days ago | 8 sessions |
| Since a 55-day breakout | it made a new 55-day high about 8 trading days ago | 8 sessions |
| All-time high | its highest closing price on record is $343.96 (set on 2021-08-05) | $343.96 |
| Given back of the 52-week move | over the past year its closes ranged ($151.43 to $306.22), and it has recovered close to two thirds of its fall from last year’s high — 63% of it. Chart-watchers call 61.8%-65% given back the "golden pocket", and this is inside it — for this company that is $247.09 to $252.04. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 62.7% |
| From the all-time high | it is 27.8% below its all-time high | -27.8% |
| Nearest price level | it is trading 1.9% above a support level at $243.76 — a price it turned at six times since 2024-11-08, most recently on 2026-01-09. Since 2024-08-26 it has 11 such levels below the current price and 4 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | -1.9% |
| All-time low | its lowest closing price on record is $17.11 (set on 2014-05-07) | $17.11 |
| Above the all-time low | it is 1352.1% above its all-time low | +1,352% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are unusually wide versus its own recent history (wider than about 86% of the past ~6 months) | 86th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $8.26 between its high and its low — about 3.3% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $8.26 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $192.33 and $265.91 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $192.33 – $229.12 – $265.91 |
| Typical daily range (% of price) | its price moves about 3.3% in a typical session — about typical for the companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 3.3% |
| Stretch from the 200-day average | it is trading 5.8 daily ranges above its 200-day average price (23.7% above it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 5.8 daily ranges above its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 0.98× |
|---|
Analyst
2
| Change in the average price target | analysts' average price target is unchanged from the prior reading | 0.0% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating has softened toward "sell" since the prior reading | 0.03 toward sell |
Candlestick patterns
2
| Since a doji | 2 sessions ago it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | 2 sessions ago |
|---|---|---|
| Since a bearish engulfing | 1 session ago it opened above the previous session's close and finished below that session's open — a "bearish engulfing" pair, where one down day more than undid the up day before it | 1 session ago |
Price gaps
3
| Gap at the open | it opened on 2026-08-24 0.3% below the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | -0.3% |
|---|---|---|
| Open gap | it gapped 2.0% above the previous close 4 sessions ago and has not traded back through the level it left behind at 238.34 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | +2.0% |
| Gap filled | a 2.1% gap down opened on 2026-08-06 has been "filled" 12 sessions ago — price traded back through the level the gap left behind, and it closed again during the very session that opened it | 12 sessions ago |
Price streaks
1
| Closing streak | it closed higher in its latest session, after a session that did not close higher — a single up day rather than a run | 1 session up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock beat the market by 30.1 percentage points (the stock gained 33.4% while the market gained 3.3%) | +30.1% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock beat the market by 52.7 percentage points (the stock gained 55.1% while the market gained 2.4%) | +52.7% |
| vs market, 6 months | over the past 6 months this stock beat the market by 30.3 percentage points (the stock gained 41.3% while the market gained 11.1%) | +30.3% |
| vs market, 12 months | over the past 12 months this stock lagged the market by 32.9 percentage points (the stock lost 14.6% while the market gained 18.3%) | -32.9% |
Signal agreement
2
| Bullish technical signals | 5 of the 9 technical signals we can compute for it are currently in a bullish state: a strong uptrend, with buyers in control, trading above its 200-day average, MACD momentum is positive, outperforming the market over 6 months, trading above the Ichimoku cloud — these describe past price behaviour, not a forecast | 5 of 9 |
|---|---|---|
| Bearish technical signals | 2 of the 9 technical signals we can compute for it are currently in a bearish state: a "death cross" — its 50-day average is below its 200-day, near the top of its 14-day range (overbought) — these describe past price behaviour, not a forecast | 2 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 36% above the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-07-17 and projected forward over today's price, the side traders read as an established uptrend, with the band below acting as the level that would have to give way. The band itself is moderate, spanning 3.2% of the share price. | +35.6% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 35% above the average price paid so far this year, so the typical buyer over that stretch is showing a gain. That average is $183.61 — a volume-weighted average of daily closes over 159 sessions, not a true tick-by-tick VWAP. | +35.3% |
|---|---|---|
| Vs the average paid since it last reported | the price is 29% above the average price paid since it last reported on 2026-06-03 (its 8-K), so the typical buyer over that stretch is showing a gain. That average is $192.55 — a volume-weighted average of daily closes over 55 sessions, not a true tick-by-tick VWAP. | +29.0% |
Price levels it has turned at before
VEEV last closed at $248.46 on 2026-08-24. Since 2024-08-26 it has turned at 11 prices below its last close and 4 above; the 3 nearest below and the 3 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $243.76 | Support | 1.9% below the last close | turned there six times · 2024-11-08 to 2026-01-09 |
| $232.56 | Support | 6.4% below the last close | turned there three times · 2025-02-26 to 2025-11-24 |
| $225.74 | Support | 9.2% below the last close | turned there six times · 2024-09-12 to 2026-01-23 |
| $272.62 | Resistance | 9.7% above the last close | turned there five times · 2025-06-20 to 2025-09-25 |
| $284.51 | Resistance | 14.5% above the last close | turned there four times · 2025-07-10 to 2025-11-07 |
| $291.17 | Resistance | 17.2% above the last close | turned there twice · 2025-06-12 to 2025-07-01 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a five-part upward sequence — what Elliott-wave chartists call an impulse — now in leg 3 of five.
This labelling fails — stops being a possible reading at all — if it closes below $179.25.
This is one of several labellings that fit the same swings, so treat it as a reading rather than the reading. It was chosen from 2 labellings that survived the rules, counting shorter readings of the same bars.
On past moves of this shape the leg has usually ended somewhere between $229.16 and $260.00 — that is where it has tended to end if the count holds, not a forecast of where the price goes.
Alternate reading: The same swings also read as a three-part correction in leg C, which fails on a close below $179.25.
This labelling was already in place when we began recording count changes on 2026-08-13, so how long it has stood is not something we can say yet.
Read from daily closes as of 2026-08-24.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading above the 200-day moving average · Tested and reclaimed 200-day support · in a strong, established uptrend (ADX) · beating the market · At the top of its 14-day range (stochastic above 80) · Near the golden pocket (has given back about two thirds of its 52-week move) | Learn: moving average · golden cross · adx · rsi · breakout · fifty two week high low
Based on daily closing prices as of 2026-08-24. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingBuy (1.93 mean, 1=Strong Buy…5=Strong Sell) — 28 analysts
- Mean price target$244.14 range $165.00 – $350.00; median $235.00
Analyst estimates, as of 2026-08-17. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for VEEV
- Consensus EPS estimate$2.22 next reporting period, as of 2026-08-17
Change over time is not available yet: it needs two readings of the same reporting period at least 30 days apart, and we have been recording these estimates since 2026-08-04. An estimate for a DIFFERENT quarter is not a revision, so a reading from before the last report is never compared with one after it.
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Revenue concentration in life sciences industry exposes company to regulatory changes, drug development cycles, and customer consolidation","High customer acquisition costs and dependency on deeper customer penetration; R&D solutions serve many early-stage pre-commercial companies that may not reach commercialization","Stock price declined 31.6% over the past year despite profitability and revenue growth, indicating market sentiment pressure or competitive concerns"]
What changed in the latest 10-Q
AI-assisted comparison of VEEV's 10-Q filed 2026-06-05 against the prior one filed 2025-11-21.
Management's Discussion & Analysis (MD&A)
- Added:
- Added 'AI' to the list of offerings in the Overview section (newer filing states offerings 'span cloud software, AI, data, and business consulting')
- Added fiscal year 2026 financial data: total revenues of $3,195 million, subscription revenues of $2,684 million, and net income of $909 million
- Added customer count data as of January 31, 2026: 1,552 total customers, 767 Commercial Solutions customers, and 1,196 R&D and Quality Solutions customers
- Added reference to Form 10-K filed on March 20, 2026 (for fiscal year ended January 31, 2026)
- Added three-month period ended April 30, 2026 revenue data showing 46% and 54% subscription revenue split and 45% and 55% total revenue split
- Added statement that subscription revenues constituted 83% of total revenues for the three months ended April 30, 2026
- Removed:
- Removed fiscal year 2023 financial data (total revenues of $2,155 million, subscription revenues of $1,733 million, net income of $488 million)
- Removed customer count data as of January 31, 2023 (1,388 total customers, 684 Commercial Solutions customers, 1,025 R&D Solutions customers)
- Removed reference to Form 10-K filed on March 24, 2025
- Removed nine-month period ended October 31, 2025 revenue data
- Removed statement that subscription services revenues constituted 84% for the nine months ended October 31, 2025
- Removed 'data services' and 'training' from the list of professional services in the Revenues section
- Reworded:
- Changed 'research and development ("R&D")' to just 'R&D' in the Overview section
- Changed terminology from 'R&D Solutions' to 'R&D and Quality Solutions' throughout the document
- Changed 'subscription services revenues' to 'subscription revenues' (removed word 'services')
- Changed 'subscription services fees' to 'subscription fees'
- Changed 'managed services related to our solutions and services related to' to 'managed services in connection with our solutions, as well as services related to'
- Changed 'data services' listing removal aligns with wording change in professional services description
- Notes:
- The newer filing represents a subsequent quarter (Q2 fiscal 2026 ended April 30, 2026) compared to the older filing (Q3 fiscal 2025 ended October 31, 2025), so some changes reflect updated period comparisons rather than document revisions
- The text appears truncated at the same point in both filings, preventing assessment of changes in any content beyond the visible portions
Risk Factors
- Added:
- Added specificity to competition risk: 'particularly in the CRM market as we transition customers from our legacy CRM application to our Vault CRM application' (2026-06-05 filing)
- Added reference to 'regulation of pharmaceutical advertising' as a life sciences industry factor (2026-06-05 filing)
- Added clarification about tariff threats: 'including the imposition of additional tariffs or threats to impose additional tariffs' (2026-06-05 filing)
- Added phrase 'faster to execute, large in scope' to description of AI-enabled cyberattacks (2026-06-05 filing)
- Removed:
- Removed specific geopolitical reference 'Russian invasion of Ukraine and the regional' from the summary bullet point; newer version only mentions 'like the conflict in the Middle East' (2025-11-21 filing had both)
- Removed 'lead to the loss of our customers to competitors' from the migration risk bullet point (2025-11-21 filing)
- Removed 'due to an increase in cyberattack attempts on us, our customers, our partners, or our technology infrastructure providers' explanatory clause (2025-11-21 filing)
- Removed 'or omissions' from 'employee or contractor error, omissions, or malfeasance' phrase (2025-11-21 filing)
- Removed phrase 'and generally are not identified until they are launched against a target' was reordered but similar content appears in both versions
- Reworded:
- Competition risk bullet changed from 'The markets in which we participate are highly competitive' to 'We face intense competition in markets in which we operate—particularly in the CRM market as we transition customers from our legacy CRM application to our Vault CRM application' (2026-06-05 vs 2025-11-21)
- Reordered risk factor bullets: 'newer solutions' adoption moved from 4th position to earlier position (2026-06-05 vs 2025-11-21)
- Geopolitical conflict phrasing changed from 'Russian invasion of Ukraine and the regional conflict in the Middle East' to just 'like the conflict in the Middle East' in summary section (2026-06-05 vs 2025-11-21)
- Changed 'imposition of tariffs' to 'imposition of additional tariffs or threats to impose additional tariffs' (2026-06-05 vs 2025-11-21)
- Removed word 'artificial intelligence' abbreviation usage changed from parenthetical definition to direct reference in some contexts (minor stylistic change)
- Removed explanatory text about why cyberattack risk may be elevated (2025-11-21 had longer explanation; 2026-06-05 shorter)
- Notes:
- The provided text from the newer filing (2026-06-05) appears truncated mid-sentence ('Moreover, our effort'), making complete comparison of the detailed risk discussion section impossible
- The older filing text (2025-11-21) also appears truncated mid-sentence ('Moreover, our efforts to detect, prevent, and remediate'), limiting assessment of later changes in that section
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
0 open-market purchases and 4 open-market sales by insiders in the last 90 days.
- Last 30 days0 buys · 3 sells ($9M) — 1 selling insider
- Last 90 days0 buys · 4 sells ($10M) — 1 selling insider
- Last 180 days0 buys · 6 sells ($10M) — 2 selling insiders
Activity heuristic: net selling (a transparent product heuristic from the counts above, not a prediction or advice)
Most recent open-market transaction: 2026-08-13. As of 2026-08-25.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about VEEV's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Congressional trading disclosures
U.S. House members publicly disclose their own, their spouse's, and dependent children's stock transactions under the STOCK Act. We hold 4 matched disclosures for VEEV from U.S. House Clerk Periodic Transaction Report filings.
Congressional trading disclosures →Institutional ownership (13F)
4 institutional 13F filers reported holding VEEV as of 2026-03-31 (quarter-end position, filed within 45 days).
- Distinct 13F filers 4
- Reported shares held 18,216,699
- Reported value $3,199,945,283
reported quarterly holdings change (2025-12-31 → 2026-03-31): 0 new, 2 increased, 2 decreased, 4 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Short interest (FINRA)
VEEV had 7,300,157 shares of reported short interest as of the 2026-07-31 FINRA settlement date (delayed, bi-monthly; not real-time).
VEEV had 4.49% of its shares outstanding sold short as of the 2026-07-31 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 5.04 days to cover at the same settlement.
- Reported short interest (shares) 7,300,157
- Short interest (% of shares outstanding) 4.49%
- Prior settlement (shares) 7,918,041
- Reported change -7.8%
- Days to cover (reported) 5.04
Reported to FINRA as of the 2026-07-31 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Salesforce
- Oracle
- SAP
- IBM
- IQVIA
- Syneos Health
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare VEEV vs…
Veeva Systems is found in…
Frequently asked questions
What does Veeva Systems (VEEV) do?
Veeva is the leading provider of industry cloud solutions for the global life sciences industry, serving pharmaceutical, biotechnology, medical device, and diagnostics companies. The company offers four major product categories—Development Cloud, Quality Cloud, Commercial Cloud, and Data Cloud—spanning cloud software, AI, data, and business consulting to support customers from R&D through commercialization.
What sector is Veeva Systems (VEEV) in?
Veeva Systems (VEEV) is classified in the Health Care sector. Its industry is Life Sciences Cloud Software. It trades on NYSE.
Who are Veeva Systems's (VEEV) competitors?
Notable peers of Veeva Systems (VEEV) include Salesforce, Oracle, SAP, IBM and IQVIA. This peer set is informational only — not financial advice.
Has there been recent Congressional stock trading in VEEV?
Yes — we hold 4 matched STOCK Act disclosures for VEEV from U.S. House Clerk Periodic Transaction Report filings. These are legally-required disclosures (often filed 30–45 days after the trade), may belong to a U.S. House member, their spouse, or a dependent child, and are not an indicator of company performance or investment advice.
Is Veeva Systems (VEEV) overbought or oversold right now?
Veeva Systems (VEEV) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 70, in the neutral middle (as of 2026-08-24). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on VEEV come from?
Fundamentals and prices come from market data, as of 2026-08-24; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-24.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.